These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
144 related articles for article (PubMed ID: 38089167)
1. A 1-year analysis from a natural history study in Chinese individuals with Duchenne muscular dystrophy. Li X; Lv J; Zhu W; Hong S; Wang Z; Chang X; Gao YX; Zhou Y; Jia C; Fang J; Patterson TA Lancet Reg Health West Pac; 2024 Jan; 42():100944. PubMed ID: 38089167 [TBL] [Abstract][Full Text] [Related]
2. Comparison of Long-term Ambulatory Function in Patients with Duchenne Muscular Dystrophy Treated with Eteplirsen and Matched Natural History Controls. Mendell JR; Khan N; Sha N; Eliopoulos H; McDonald CM; Goemans N; Mercuri E; Lowes LP; Alfano LN; J Neuromuscul Dis; 2021; 8(4):469-479. PubMed ID: 33523015 [TBL] [Abstract][Full Text] [Related]
3. Exploring the relationship between North Star Ambulatory Assessment and Health Utilities Index scores in Duchenne muscular dystrophy. Audhya I; Rogula B; Szabo SM; Feeny D; Bolatova T; Gooch K Health Qual Life Outcomes; 2023 Jul; 21(1):76. PubMed ID: 37468890 [TBL] [Abstract][Full Text] [Related]
4. Characteristics of disease progression and genetic correlation in ambulatory Iranian boys with Duchenne muscular dystrophy. Zamani G; Hosseinpour S; Ashrafi MR; Mohammadi M; Badv RS; Tavasoli AR; Akbari MG; Bereshneh AH; Malamiri RA; Heidari M BMC Neurol; 2022 May; 22(1):162. PubMed ID: 35501714 [TBL] [Abstract][Full Text] [Related]
5. Efficacy and Safety of Vamorolone in Duchenne Muscular Dystrophy: A 30-Month Nonrandomized Controlled Open-Label Extension Trial. Mah JK; Clemens PR; Guglieri M; Smith EC; Finkel RS; Tulinius M; Nevo Y; Ryan MM; Webster R; Castro D; Kuntz NL; McDonald CM; Damsker JM; Schwartz BD; Mengle-Gaw LJ; Jackowski S; Stimpson G; Ridout DA; Ayyar-Gupta V; Baranello G; Manzur AY; Muntoni F; Gordish-Dressman H; Leinonen M; Ward LM; Hoffman EP; Dang UJ; JAMA Netw Open; 2022 Jan; 5(1):e2144178. PubMed ID: 35076703 [TBL] [Abstract][Full Text] [Related]
6. Interventions for preventing and treating cardiac complications in Duchenne and Becker muscular dystrophy and X-linked dilated cardiomyopathy. Bourke JP; Bueser T; Quinlivan R Cochrane Database Syst Rev; 2018 Oct; 10(10):CD009068. PubMed ID: 30326162 [TBL] [Abstract][Full Text] [Related]
7. Natural History of Steroid-Treated Young Boys With Duchenne Muscular Dystrophy Using the NSAA, 100m, and Timed Functional Tests. Miller NF; Alfano LN; Iammarino MA; Connolly AM; Moore-Clingenpeel M; Powers BR; Tsao CY; Waldrop MA; Flanigan KM; Mendell JR; Lowes LP Pediatr Neurol; 2020 Dec; 113():15-20. PubMed ID: 32979653 [TBL] [Abstract][Full Text] [Related]
8. Disease progression modeling of the North Star Ambulatory Assessment for Duchenne Muscular Dystrophy. Hibma JE; Jayachandran P; Neelakantan S; Harnisch LO CPT Pharmacometrics Syst Pharmacol; 2023 Mar; 12(3):375-386. PubMed ID: 36718719 [TBL] [Abstract][Full Text] [Related]
9. Corticosteroids for the treatment of Duchenne muscular dystrophy. Matthews E; Brassington R; Kuntzer T; Jichi F; Manzur AY Cochrane Database Syst Rev; 2016 May; 2016(5):CD003725. PubMed ID: 27149418 [TBL] [Abstract][Full Text] [Related]
10. Investigating the role of dystrophin isoform deficiency in motor function in Duchenne muscular dystrophy. Chesshyre M; Ridout D; Hashimoto Y; Ookubo Y; Torelli S; Maresh K; Ricotti V; Abbott L; Gupta VA; Main M; Ferrari G; Kowala A; Lin YY; Tedesco FS; Scoto M; Baranello G; Manzur A; Aoki Y; Muntoni F J Cachexia Sarcopenia Muscle; 2022 Apr; 13(2):1360-1372. PubMed ID: 35083887 [TBL] [Abstract][Full Text] [Related]
11. The NorthStar Ambulatory Assessment in Duchenne muscular dystrophy: considerations for the design of clinical trials. Ricotti V; Ridout DA; Pane M; Main M; Mayhew A; Mercuri E; Manzur AY; Muntoni F; J Neurol Neurosurg Psychiatry; 2016 Feb; 87(2):149-55. PubMed ID: 25733532 [TBL] [Abstract][Full Text] [Related]
12. Efficacy and safety of vamorolone in Duchenne muscular dystrophy: An 18-month interim analysis of a non-randomized open-label extension study. Smith EC; Conklin LS; Hoffman EP; Clemens PR; Mah JK; Finkel RS; Guglieri M; Tulinius M; Nevo Y; Ryan MM; Webster R; Castro D; Kuntz NL; Kerchner L; Morgenroth LP; Arrieta A; Shimony M; Jaros M; Shale P; Gordish-Dressman H; Hagerty L; Dang UJ; Damsker JM; Schwartz BD; Mengle-Gaw LJ; McDonald CM; PLoS Med; 2020 Sep; 17(9):e1003222. PubMed ID: 32956407 [TBL] [Abstract][Full Text] [Related]
13. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas. Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557 [TBL] [Abstract][Full Text] [Related]
14. Duchenne Muscular Dystrophy from Brain to Muscle: The Role of Brain Dystrophin Isoforms in Motor Functions. Wijekoon N; Gonawala L; Ratnayake P; Amaratunga D; Hathout Y; Mohan C; Steinbusch HWM; Dalal A; Hoffman EP; de Silva KRD J Clin Med; 2023 Aug; 12(17):. PubMed ID: 37685704 [TBL] [Abstract][Full Text] [Related]